MXPA05008148A - Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transformante (tgf). - Google Patents

Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transformante (tgf).

Info

Publication number
MXPA05008148A
MXPA05008148A MXPA05008148A MXPA05008148A MXPA05008148A MX PA05008148 A MXPA05008148 A MX PA05008148A MX PA05008148 A MXPA05008148 A MX PA05008148A MX PA05008148 A MXPA05008148 A MX PA05008148A MX PA05008148 A MXPA05008148 A MX PA05008148A
Authority
MX
Mexico
Prior art keywords
tgf
growth factor
transforming growth
inhibitors
fused heteroaromatic
Prior art date
Application number
MXPA05008148A
Other languages
English (en)
Inventor
Shavnya Andre
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32962623&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05008148(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MXPA05008148A publication Critical patent/MXPA05008148A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

Se describen nuevos compuestos heteroaromaticos condensados, incluidos sus derivados, intermedios para su preparacion, composiciones farmaceuticas que los contienen y su uso medicinal. Los compuestos de la presente invencion son potentes inhibidores de la ruta senalizadora del factor de crecimiento transformante ("TGF")-(. Son utiles en el tratamiento de enfermedades relacionadas con TGF-( incluidas, por ejemplo, cancer y enfermedades fibroticas.
MXPA05008148A 2003-03-04 2004-02-23 Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transformante (tgf). MXPA05008148A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45168303P 2003-03-04 2003-03-04
PCT/IB2004/000532 WO2004078110A2 (en) 2003-03-04 2004-02-23 Fused imizadoles as transforming growth factor (tgf) inhibitors

Publications (1)

Publication Number Publication Date
MXPA05008148A true MXPA05008148A (es) 2005-09-30

Family

ID=32962623

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05008148A MXPA05008148A (es) 2003-03-04 2004-02-23 Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transformante (tgf).

Country Status (14)

Country Link
US (2) US7417041B2 (es)
EP (1) EP1601676A2 (es)
JP (1) JP2006519249A (es)
AR (1) AR043449A1 (es)
BR (1) BRPI0407999A (es)
CA (1) CA2517933C (es)
GT (1) GT200400032A (es)
MX (1) MXPA05008148A (es)
NL (1) NL1025623C2 (es)
PA (1) PA8595001A1 (es)
PE (1) PE20050306A1 (es)
TW (1) TW200504069A (es)
UY (1) UY28214A1 (es)
WO (1) WO2004078110A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80295C2 (en) 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
UA80296C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
AU2003259475A1 (en) * 2002-09-18 2004-04-08 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (TGF) inhibitors
AP2005003264A0 (en) * 2002-09-18 2005-03-31 Pfizer Prod Inc Novel imidazole compounds as transforming growth factor (TGD) inhibitors.
JP2008516962A (ja) * 2004-10-15 2008-05-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 血管傷害を治療する方法
CA2594325A1 (en) * 2004-12-28 2006-07-06 Takeda Pharmaceutical Company Limited Condensed imidazole compound and use thereof
WO2007028051A2 (en) * 2005-09-02 2007-03-08 Abbott Laboratories Novel imidazo based heterocycles
CN101330914A (zh) * 2005-12-16 2008-12-24 爱尔康公司 使用alk5调节剂控制眼内压
AP3433A (en) * 2005-12-21 2015-10-31 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modultors
EP2068869A4 (en) * 2006-10-06 2011-05-25 Abbott Lab NEW IMIDAZOTHIAZOLE AND IMIDAZOXAZOLE
NO346024B1 (no) 2006-11-22 2022-01-03 Incyte Holdings Corp Imidazotriaziner og imidazopyrimidiner som kinaseinhibitorer
CN101652069A (zh) * 2007-03-27 2010-02-17 艾博特公司 新的基于咪唑并的杂环化合物
BRPI0809998B8 (pt) 2007-04-03 2021-05-25 Array Biopharma Inc composto de imidazo[1,2-a] piridina como inibidores do receptor tirosina quinase, seus usos, seus processos de preparação e composições farmacêuticas
WO2008133192A1 (ja) * 2007-04-19 2008-11-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
CN101678014B (zh) * 2007-05-21 2012-12-12 Sgx药品公司 杂环激酶调节剂
JP2010529031A (ja) * 2007-05-29 2010-08-26 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害剤としてのナフチリジン誘導体
US8188083B2 (en) * 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
PT2193133E (pt) * 2007-09-27 2015-10-22 Fundación Ct Nac De Investigaciones Oncológicas Carlos Iii Imidazolotiadiazóis para utilização como inibidores de proteína quinases
EP2307425B1 (en) 2008-07-29 2014-03-26 Merck Patent GmbH Imidazothiadiazoles derivatives
EA022753B1 (ru) 2009-04-02 2016-02-29 Фундасьон Сентро Насиональ Де Инвестигасьонес Онколохикас Карлос Iii Имидазотиадиазолы для применения в качестве ингибиторов киназ
FR2945289A1 (fr) * 2009-05-11 2010-11-12 Sanofi Aventis Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo°2,1-b! °1,3,4!thiadiazole, leur preparation et leur application en therapeutique
KR20180051676A (ko) 2009-10-16 2018-05-16 멜린타 테라퓨틱스, 인크. 항미생물성 화합물 및 이의 제조 방법 및 사용 방법
US20120220581A1 (en) 2009-10-30 2012-08-30 Janssen-Cilag, S.A. IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
KR101692126B1 (ko) 2009-12-18 2017-01-02 미쓰비시 타나베 파마 코퍼레이션 신규 항혈소판약
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
US10604523B2 (en) 2011-06-27 2020-03-31 Janssen Pharmaceutica Nv 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
CA2841252C (en) 2011-07-13 2019-02-26 Sk Chemicals Co., Ltd. 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors
WO2013181326A1 (en) 2012-05-30 2013-12-05 Cornell University Generation of functional and durable endothelial cells from human amniotic fluid-derived cells
JP6426603B2 (ja) 2012-06-26 2018-11-21 ヤンセン ファーマシューティカ エヌ．ベー． 神経障害または代謝障害の治療に使用するための、１−アリール−４−メチル−［１，２，４］トリアゾロ［４，３−ａ］−キノキサリン化合物などのＰＤＥ２阻害剤とＰＤＥ１０阻害剤との組合せ
CN104411314B (zh) 2012-07-09 2017-10-20 詹森药业有限公司 磷酸二酯酶10的抑制剂
US20140120116A1 (en) * 2012-10-26 2014-05-01 The Chinese University Of Hong Kong Treatment of cancer using smad3 inhibitor
WO2014197421A1 (en) 2013-06-05 2014-12-11 Biotime, Inc. Compositions and methods for induced tissue regeneration in mammalian species
ES2813875T3 (es) 2014-01-01 2021-03-25 Medivation Tech Llc Compuestos y procedimientos de uso
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
JP6789941B2 (ja) * 2014-11-21 2020-11-25 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｔｇｆ−ベータ阻害剤としての縮合イミダゾール誘導体
TW201630907A (zh) * 2014-12-22 2016-09-01 必治妥美雅史谷比公司 ＴＧＦβＲ拮抗劑
MX2017011616A (es) 2015-03-11 2018-04-11 Melinta Therapeutics Inc Compuestos antimicrobianos y métodos para hacerlos y usarlos.
AU2019396360A1 (en) 2018-12-11 2021-05-27 Theravance Biopharma R&D Ip, Llc Naphthyridine and quinoline derivatives useful as ALK5 inhibitors
EP4061809A1 (en) 2019-11-22 2022-09-28 Theravance Biopharma R&D IP, LLC Substituted 1,5-naphthyridines or quinolines as alk5 inhibitors

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (es) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4719218A (en) * 1985-12-12 1988-01-12 Smithkline Beckman Corporation Pyrrolo[1,2-a]imidazole and pyrrolo[1,2-a]pyridine derivatives and their use as 5-lipoxygenase pathway inhibitor
ZW24186A1 (en) 1985-12-12 1987-07-08 Smithkline Beckman Corp Inhibition of the 5-lipoxygenase pathway
US5002941A (en) 1985-12-12 1991-03-26 Smithkline Beecham Corporation Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors
IL83467A0 (en) 1986-08-15 1988-01-31 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
MY103766A (en) * 1987-09-02 1993-09-30 Smithkline Beckman Corp Pyrrolo[1,2-a]imidazole and imidazo[1,2-a] pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors
US5656644A (en) 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
WO1996030347A1 (en) 1995-03-30 1996-10-03 Pfizer Inc. Quinazoline derivatives
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
IL132736A0 (en) 1997-05-22 2001-03-19 Searle & Co 3(5)-Heteroaryl substituted pyrazoles as p38 kinase inhibitors
US6087381A (en) 1997-05-22 2000-07-11 G. D. Searle & Company Pyrazole derivatives as p38 kinase inhibitors
ES2187473T3 (es) 1999-04-09 2003-06-16 Smithkline Beecham Corp Triarylimidazoles.
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
EP1349851A4 (en) 2000-11-16 2004-09-08 Smithkline Beecham Corp COMPOUNDS
GB0027987D0 (en) 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds
GB0100762D0 (en) 2001-01-11 2001-02-21 Smithkline Beecham Plc Novel use
GB0102672D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
JP2004521901A (ja) 2001-02-02 2004-07-22 グラクソ　グループ　リミテッド Ｔｇｆ阻害剤としてのピラゾール
WO2002066462A1 (en) 2001-02-02 2002-08-29 Glaxo Group Limited Pyrazole derivatives against tgf overexpression
ES2260415T3 (es) 2001-03-09 2006-11-01 Pfizer Products Inc. Triazolopiridinas como agentes antiimflamatorios.
CA2440211A1 (en) 2001-03-09 2002-09-19 Pfizer Products Inc. Benzimidazole anti-inflammatory compounds
EP1247810B1 (en) 2001-04-04 2005-09-07 Pfizer Products Inc. Novel benzotriazoles anti-inflammatory compounds
US7196095B2 (en) 2001-06-25 2007-03-27 Merck & Co., Inc. (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
GB0217783D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
JP2005539000A (ja) * 2002-07-31 2005-12-22 スミスクライン・ビーチャム・コーポレイション Ａｌｋ５阻害剤としての２−フェニルピリジン−４−イル誘導体
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
CA2498237A1 (en) * 2002-09-13 2004-03-25 Merck & Co., Inc. Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators
KR20050057415A (ko) 2002-09-18 2005-06-16 화이자 프로덕츠 인코포레이티드 전환성장인자(ｔｇｆ) 억제제로서의 신규한 싸이아졸 및 옥사졸 화합물
AU2003259475A1 (en) * 2002-09-18 2004-04-08 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (TGF) inhibitors
PL375973A1 (en) 2002-09-18 2005-12-12 Pfizer Products Inc. Novel isothiazole and isoxazole compounds as transforming growth factor (tgf) inhibitors
AP2005003264A0 (en) * 2002-09-18 2005-03-31 Pfizer Prod Inc Novel imidazole compounds as transforming growth factor (TGD) inhibitors.
CA2497971A1 (en) * 2002-09-18 2004-04-01 Pfizer Products Inc. Triazole derivatives as transforming growth factor (tgf) inhibitors

Also Published As

Publication number Publication date
WO2004078110A2 (en) 2004-09-16
AR043449A1 (es) 2005-07-27
GT200400032A (es) 2004-10-21
CA2517933C (en) 2009-05-12
JP2006519249A (ja) 2006-08-24
US7417041B2 (en) 2008-08-26
WO2004078110A3 (en) 2004-11-11
TW200504069A (en) 2005-02-01
EP1601676A2 (en) 2005-12-07
US20040176390A1 (en) 2004-09-09
PA8595001A1 (es) 2004-09-28
BRPI0407999A (pt) 2006-03-07
CA2517933A1 (en) 2004-09-16
NL1025623A1 (nl) 2004-09-07
PE20050306A1 (es) 2005-05-16
NL1025623C2 (nl) 2005-03-14
UY28214A1 (es) 2004-09-30
US20080275235A1 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
MXPA05008148A (es) Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transformante (tgf).
MXPA05009245A (es) Nuevos compuestos de pirazina como inhibidores del factor de crecimiento transformante (tgf).
CA2498047A1 (en) Novel imidazole compounds as transforming growth factor (tgf) inhibitors
WO2004026306A3 (en) Pyrazole derivatives as transforming growth factor (tgf) inhibitors
WO2004026863A8 (en) Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
NO20051010L (no) Triazolderivater som transformerende vekst faktor (TGF) inhibitorer
NO20051852L (no) Nye isotiazol- og isoksazolforbindelser samt transformerende vekstfaktor (TGF)-inhibitorer.
MY129422A (en) Medicinal compounds
NZ516347A (en) Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
PL1687305T3 (pl) Pochodne 1H-imidazochinolin jako inhibitory kinaz białkowych
AU2003222841A1 (en) Phenethanolamine derivatives
RS60503A (en) Substituted alkylamine derivatives and methods of use
GB0112348D0 (en) Compounds
ES2187300A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
PL1727817T3 (pl) Pochodne azabicyklooktan-3-onu i ich zastosowanie
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
MEP42908A (en) Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use of the same as medicaments, and medicament containing such compounds
MY139613A (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
AP2002002572A0 (en) Novel substituted pyrazol(4,3-e) diazepines, pharmaceutical compositions containing them, as medical products and processes for preparing them
PE20030236A1 (es) Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados
HK1097548A1 (en) Novel indeno
DOP2003000712A (es) Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf)
MY135855A (en) "pyrrolopyrimidinone derivatives, process of preparation and use"
CR7749A (es) Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf)

Legal Events

Date Code Title Description
FG Grant or registration